Incidentally Found Rectal Carcinoid Tumor in a 46-Year-Old Female: The Potential for Complications and the Importance of Screening Guidelines

Authors

  • Rebecca Lapides Fourth-year Medical Student. Robert Larner, M.D., College of Medicine at the University of Vermont, Burlington, USA.
  • Akash Shah MD. Department of Internal Medicine, Nuvance Health, Danbury, USA.
  • Shubhneet Bal MD. Department of Pathology, Nuvance Health, Danbury, USA.
  • Vidhun Ramapriya MD. Department of Pathology, Nuvance Health, Danbury, USA.

DOI:

https://doi.org/10.5195/ijms.2023.2346

Keywords:

Carcinoid Tumor, Hypertension, Diabetes Mellitus, Type 2, Colonoscopy, Early Detection of Cancer

Abstract

BACKGROUND: Carcinoid tumors are rare neuroendocrine tumors that can be found in the gastrointestinal tract as well as other areas throughout the body. The neurosecretory nature of these tumors can have implications for other chronic diseases that patients may have, including diabetes and hypertension. Certain treatments that may be implemented for patients that have carcinoid tumors, such as somatostatin analogs and Everolimus, can also alter blood glucose control. This highlights the importance of diagnosing and treating carcinoid tumors as early as possible to avoid complications associated with metastasis and more intense treatment. With more advanced disease, clinicians should consider the possible effects of carcinoid tumors and their treatments on other chronic conditions as they manage the patient. For gastrointestinal carcinoid tumors, colonoscopy screening guidelines are incredibly important to counsel patients on, as resection can yield a complete cure for carcinoid tumors when they are found at an early stage.

THE CASE: We describe the case of an incidentally diagnosed rectal carcinoid tumor in a 46-year-old female patient with a history of type 2 diabetes mellitus and hypertension. This tumor was discovered on colonoscopy, which had been delayed due to complications following a surgical procedure that the patient had recently undergone.

CONCLUSION: Carcinoid tumors are quite rare, however, the incidence of neuroendocrine tumors, including gastrointestinal carcinoid tumors, is growing. Thus, it is important to consider the implications of such tumors on pre-existing chronic conditions, such as diabetes and hypertension. Also, more research efforts should be directed towards standardizing the treatment protocol for such tumors, specifically rectal carcinoid tumors, and counseling patients on the importance of screening guidelines. When rectal carcinoid tumors are caught early, complete surgical resection can be curative, which is ideal. However, with more advanced disease, symptoms of the tumor itself as well as necessary treatments can impact other chronic conditions, possibly requiring modifications to a patient’s prior medication regimen. Fortunately, the carcinoid tumor in the described patient was not advanced enough to cause significant alteration in her other chronic conditions, however, this case is still a great example of how carcinoid tumors can arise asymptomatically, which is why it is important for the astute clinician to counsel on screening recommendations. This emphasizes the importance of using a team-based approach to ensure that the carcinoid tumor is diagnosed and adequately treated without significantly affecting other conditions so that patients can achieve optimal outcomes for each condition being managed. It also highlights the crucial importance of screening guidelines so that conditions can be caught early to mitigate downstream consequences.

Metrics

Metrics Loading ...

References

Pinchot SN, Holen K, Sippel RS, & Chen H. (2008). Carcinoid tumors. The oncologist, 13(12), 1255-1269.

Viana C, Marques I, Staubus A, & Martins SF. (2019). Rectal carcinoid tumor: diagnosis and management. Journal of Coloproctology (Rio de Janeiro), 39, 184-189.

Kusne, Y. N., Kosiorek, H. E., Buras, M. R., Verona, P. M., Coppola, K. E., Rone, K. A., ... & Karlin, N. J. (2021). Implications of neuroendocrine tumor and diabetes mellitus on patient outcomes and care: a matched case–control study. Future Science OA, 7(5), FSO684.

Mills, K. T., Stefanescu, A., & He, J. (2020). The global epidemiology of hypertension. Nature Reviews Nephrology, 16(4), 223-237.

Das, S., & Dasari, A. (2021). Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?. Current oncology reports, 23, 1-7.

Bodei, L., Ćwikla, J. B., Kidd, M., & Modlin, I. M. (2017). The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors. Journal of thoracic disease, 9(Suppl 15), S1511.

https://www.health.ny.gov/statistics/cancer/registry/abouts/carcinoid.htm#:~:text=Carcinoid%20tumors%20are%20rare%2C%20making,one%20percent%20of%20all%20cancers

Kwaan, M. R., Goldberg, J. E., & Bleday, R. (2008). Rectal carcinoid tumors: review of results after endoscopic and surgical therapy. Archives of Surgery, 143(5), 471-475.

https://www.dana-farber.org/neuroendocrine-and-carcinoid-tumors-program/faq/

Ngamruengphong, S., Kamal, A., Akshintala, V., Hajiyeva, G., Hanada, Y., Chen, Y. I., ... & Khashab, M. A. (2019). Prevalence of metastasis and survival of 788 patients with T1 rectal carcinoid tumors. Gastrointestinal endoscopy, 89(3), 602-606.

Mota, J. M., Sousa, L. G., & Riechelmann, R. P. (2016). Complications from carcinoid syndrome: review of the current evidence. Ecancermedicalscience, 10.

Capurso G, Falconi M, Panzuto F et al. Risk factors for sporadic pancreatic endocrine tumors: a case-control study of prospectively evaluated patients. Am. J. Gastroenterol. 104(12), 3034–3041 (2009).

Ben Q, Zhong J, Fei J et al. Risk factors for sporadic pancreatic neuroendocrine tumors: a case-control study. Sci. Rep. 6, 36073 (2016).

Sandini M, Strobel O, Hank T et al. Pre-operative dysglycemia is associated with decreased survival in patients with pancreatic neuroendocrine neoplasms. Surgery 167(3), 575–580 (2020).

Umlauft M, Radojewski P, Spanjol PM et al. Diabetes mellitus and its effects on all-cause mortality after radiopeptide therapy for neuroendocrine tumors. J. Nucl. Med. 58(1), 97–102 (2017).

Fan Z, Gong Y, Huang Q et al. Diabetes is associated with the metastasis of pancreatic neuroendocrine tumors. Pancreas 49(6), 751–756 (2020).

Herold, Z., Doleschall, M., & Somogyi, A. (2021). Role and function of granin proteins in diabetes mellitus. World Journal of Diabetes, 12(7), 1081.

Modlin, I. M., Latich, I., Kidd, M., Zikusoka, M., & Eick, G. (2006). Therapeutic options for gastrointestinal carcinoids. Clinical Gastroenterology and Hepatology, 4(5), 526-547.

Pusceddu, S., Verzoni, E., Prinzi, N., Mennitto, A., Femia, D., Grassi, P., ... & Procopio, G. (2017). Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. Therapeutic Advances in Medical Oncology, 9(3), 183-188.

Mehta, S. J., Morris, A. M., & Kupfer, S. S. (2021). Colorectal Cancer Screening Starting at Age 45 Years—Ensuring Benefits Are Realized by All. JAMA network open, 4(5), e2112593-e2112593.

Downloads

Published

2023-12-19

How to Cite

Lapides, R., Shah, A., Bal, S., & Ramapriya, V. (2023). Incidentally Found Rectal Carcinoid Tumor in a 46-Year-Old Female: The Potential for Complications and the Importance of Screening Guidelines . International Journal of Medical Students, 11, S105. https://doi.org/10.5195/ijms.2023.2346

Issue

Vol 11. (2023): Supplement 1

Section

Abstracts of the WCMSR

Categories

License

Copyright (c) 2023 Rebecca Lapides, Akash Shah, Shubhneet Bal, Vidhun Ramapriya

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

  1. The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
  2. Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
  3. The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
    1. Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site; with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
    2. The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgment of its initial publication in this journal.
    3. Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
    4. Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
    5. The Author represents and warrants that:
      1. the Work is the Author’s original work;
      2. the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
      3. the Work is not pending review or under consideration by another publisher;
      4. the Work has not previously been published;
      5. the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
      6. the Work contains no libel, invasion of privacy, or other unlawful matter.
    6. The Author agrees to indemnify and hold Publisher harmless from the Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.

Enforcement of copyright

The IJMS takes the protection of copyright very seriously.

If the IJMS discovers that you have used its copyright materials in contravention of the license above, the IJMS may bring legal proceedings against you seeking reparation and an injunction to stop you using those materials. You could also be ordered to pay legal costs.

If you become aware of any use of the IJMS' copyright materials that contravenes or may contravene the license above, please report this by email to contact@ijms.org

 

Infringing material

If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to contact@ijms.org